ACCESS PACK EXPO XPRESS ONLINE TODAY
ACCESS PACK EXPO XPRESS ONLINE TODAY. Content is available on-demand through November 30th.
LEARN MORE

The First CRISPR Drug Could Launch Next Year

The first approved gene-editing drug will likely treat a rare blood disorder, and launch in 2023.

Illustration Kilobaser Blog Crispr 72 2 1024x576

A recent Fast Company article discussed a new development in the world of gene-editing. Previous mentions of CRISPR have alluded to a futuristic medical utopia where genetic ailments are edited out of existence like white-out on a rough draft. Though the technology won Jennifer Doudna and Emmanuelle Charpentier the 2020 Nobel Prize in Chemistry, we still haven’t seen a practical application we can wrap our heads around. Until now. 

Vertex, a company focused on rare diseases, teamed up with CRISPR Therapeutics to develop a therapy to treat a rare genetic blood disorders like beta thalassemia and sickle cell disease. The drug is called exa-cel (an abbreviation of exagamglogene autotemcel), and it cost nearly a billion dollars to develop. Apparently, the drug rids patients of the need for blood transfusions, and the complications that come with them. Exa-cel is expected to seek regulatory approval in the U.S., U.K., and Europe by the end of 2022, which means it could receive marketing authorization in 2023.

Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Take Quiz
Test Your Supply Chain Smarts
Access On-Demand Content Today
Discover innovative solutions for packaging and processing, automation, sustainability, e-commerce and more.
LEARN MORE
Access On-Demand Content Today